Seelos Therapeutics (SEEL) Stock Analysis

What Seelos Therapeutics does

Seelos Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to the discovery, development, and eventual commercialization of innovative therapies. These treatments primarily target central nervous system (CNS), respiratory, and various other medical conditions. The company's pipeline includes several key clinical-stage candidates. Foremost among these is SLS-002, an intranasally administered racemic ketamine, being investigated for rapidly alleviating acute suicidal ideation and behavior in individuals with major depressive disorder (MDD). Another significant program, SLS-005, acts as a protein stabilizer, addressing amyotrophic lateral sclerosis (ALS) and Sanfilippo syndrome. Additionally, SLS-006 is a partial dopamine agonist under development for the treatment of Parkinson's disease (PD). Beyond its clinical efforts, Seelos maintains a robust preclinical portfolio exploring novel mechanisms. This includes SLS-007, an anti-alpha-synuclein peptidic inhibitor designed to combat Parkinson's disease, and SLS-008, an orally bioavailable antagonist targeting chemoattractant receptor-homologous molecule, intended for chronic inflammatory conditions such as asthma and specific pediatric orphan diseases. Other early-stage candidates comprise SLS-004 for Parkinson's disease; SLS-010, an oral histamine H3A receptor antagonist aimed at narcolepsy and related sleep disorders; and SLS-012, an injectable formulation for managing post-operative pain. Founded in 1987, Seelos Therapeutics, Inc. operates from its headquarters situated in New York, New York.

Key metrics

ETFs linked to SEEL

Broad-market and Healthcare sector ETFs an investor holding Seelos Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how SEEL fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Seelos Therapeutics?

Seelos Therapeutics trades under the ticker SEEL on NASDAQ.

Which exchange is SEEL listed on?

SEEL is listed on NASDAQ.

What sector does Seelos Therapeutics operate in?

Seelos Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze SEEL in a portfolio?

PortView shows SEEL's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.